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Dear Sirs,
We report a case of disseminated histoplasmosis in a 63-
year-old lung transplant (LT) recipient in Italy. To our
knowledge, this is the first autochthonous case documented
in a solid organ transplant (SOT) recipient from a nonen-
demic area. Histoplasma capsulatum is endemic to certain
parts of Central America and mid-western United States; in
contrast, its presence as an autochthonous fungus in Eur-
ope is still controversial [1]. In Italy, the existence of
H. capsulatum in soils has been described, predominantly
in the Po valley area [2]. Around 40 cases of histoplasmosis
have been reported in Italy since 1980, mainly among trav-
elers returning from endemic areas and in human immu-
nodeficiency virus (HIV)-infected patients [2]. Infection by
H. capsulatum occurs more often in immunocompromised
hosts with T-cell defects [3]. Nevertheless, while incidence
rates of histoplasmosis can reach 5% in HIV-infected
patients, a very low number of cases are reported among
SOT recipients [3–6].
In our case, a male recipient of bilateral LT for sarcoido-
sis presented 11 years after transplant with a 4-week history
of productive cough, progressive shortness of breath, and
diarrhea. He worked as an industrial maintenance techni-
cian and resided in northeast Italy (Veneto and Friuli Vene-
zia Giulia regions), without reporting any travel abroad
before or after LT. At presentation, his immunosuppressive
regimen included tacrolimus (0.5 mg BID), mycophenolate
mofetil (1 g BID), and prednisone (15 mg/day). A chest CT
scan revealed a nodular consolidation in the right upper
lobe, multiple diffuse bilateral patchy lung opacities, and
mediastinal lymphoadenopathies. Laboratory tests showed
acute renal failure, pancytopenia with lymphopenia (260
cells/mmc), increased LDH levels, and a low PaO2/FiO2
ratio (200 mmHg). Septic disseminated intravascular coag-
ulation (DIC) was suspected due to hemolytic anemia,
decreased fibrinogen levels, and increased procalcitonin.
The patient was placed on an antimicrobial regimen of me-
ropenem, amikacin, and linezolid. Immunosuppression
was reduced and methylprednisone was added due to
severe respiratory distress. A repeat CT scan showed a
worsening of disseminated micronodular lesions and
increased chest consolidations. At hospital day 7, he was
transferred to the intensive care unit and intubated. Caspo-
fungin was empirically started and switched within 48 h to
liposomal amphotericin B (5 mg/kg/day) to extend anti-
fungal coverage. Bronchoalveolar lavage (BAL) was nega-
tive for Pneumocystits jirovecii oocystis, while
galactomannan (GM) antigen was positive in three consec-
utive determinations (6.9, 4.1, and 4.8 respectively). BAL
and bone marrow (BM) samples grew yeast forms morpho-
logically consistent with H. capsulatum. White, cottony col-
onies developed on Sabouraud’s dextrose agar. Nucleotide
sequence analysis identified H. capsulatum var. capsulatum.
Despite antifungal therapy and aggressive resuscitation
measures, the patient progressed to multi-organ failure and
died after 25 days of hospitalization.
Our report can be classified as a proven case of dissemi-
nated histoplasmosis. In fact, both compatible clinical man-
ifestations and microbiological evidence of Histoplasma in
BAL and BM were seen. The disease acquisition was proba-
bly due to post-transplant environmental exposure. Late
presentation after LT, disease severity, and BM culture pos-
itivity were distinctive features of our report.
As summarized in Table 1, only 10 cases of histoplasmo-
sis in lung transplant (LT) recipients from five centers
across the United States have been published to date [5–7].
Although histoplasmosis has been reported mainly in liver
and kidney transplants, differences in prevalence among
SOT groups are noticeable [4–6,8]. Three out of 14 cases
(21%) were reported in LT recipients over a period of
10 years from the Cleveland Clinic [5]. Afterward, a multi-
center study encompassing 152 cases of histoplasmosis in
SOT reckoned nine cases (5%) in LT recipients [6]. In vari-
ous studies including SOT recipients, histoplasmosis
showed a median time from transplant to diagnosis
between 10.5 and 17 months [4–6,8]. Early post-transplant
presentation correlated with poor outcomes [6]. Mortality
rates ranged from 0 to 13%, with most deaths occurring
within the first 3 weeks following diagnosis [5,6,8]. Com-
pared with the above-mentioned case series, Table 1
evinces higher mortality rates (3/11, 27%) and a longer
median time to histoplasmosis presentation (57 months,
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range 10–144) in LT compared with other SOT. A delay in
disease presentation for LT recipients could be postulated
due to the widespread use of antifungal prophylaxis after
LT [5].
A prompt diagnosis of histoplasmosis requires reliable
diagnostic tests. While serology is rarely useful, tests for
antigens are frequently positive (Table 1) [1,5,6]. However,
antigen detection is not available in all countries and is not
performed at our center. Microbiological cultures can be
helpful: rates of Histoplasma isolation from BAL and blood
cultures yielded positive results in 55% of LT. BM cultures,
taken to investigate the cause of pancytopenia, were indica-
tive of Histoplasma infection in LT in only one other case
[5]. Amphotericin B (AmB), which is often initiated in
severe cases until clinical stability is reached [9], was used
in 80% of LT recipients (Table 1).
The management of histoplasmosis in SOT can be chal-
lenging, especially in areas where physicians are less familiar
with the recognition of the disease. Due to the paucity of
known cases, the Infectious Diseases Society of America
(IDSA) guidelines did not include recommendations spe-
cific to this patient population [9]. In addition, features of
histoplasmosis may contribute to a delay in the correct
diagnosis: clinical manifestations can occur late after trans-
plant and be prolonged and nonspecific, laboratory and
radiological results may be similar to other opportunistic
infections, and microbiological tests, such as Aspergillus
GM, can be falsely positive [10]. As Aspergillus causes the
majority of lung infections in LT, less common fungi are
still hardly considered in the differential diagnosis. Thus,
histoplasmosis might be underdiagnosed and underesti-
mated in this group.
For these reasons, a timely diagnosis through laboratories
with mycological expertise and a prompt start of an
adequate antifungal treatment should be undertaken if his-
toplasmosis is suspected. Furthermore, due to the severity of
the disease in LT recipients, antifungal prophylaxis is advo-
cated. Finally, as atypical and delayed presentations are not
infrequent, a high level of vigilance and a strict epidemiologi-
cal surveillance should be maintained for SOT recipients in
those areas where the disease occurrence is less expected.
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Table 1. Review of published cases of histoplasmosis in lung transplant recipients and summary of current case.
Source Age/Sex
Time post-LT
(months) Country Regimen
Urine/
Serology
Histology/
Culture Treatment Outcome
Cuellar-Rodriguez
et al. [5]
41/M 10 OH (US) CyA, Pr, MMF +/ +/ND AmB, Vor Cured
52/M 47 OH (US) SIR, Pr, MMF /ND +/ND AmB, Itr Cured
64/M 83 OH (US) AZA, Pr, CyA +/+ +/+ AmB, Vor Expired†
Shah et al. [7] 43/M 10* OH (US) ND / +/+ Itr, Vor Cured
Assi et al. [6] 59/M 23 AL (US) CyA, MMF, Pr +/ND +/+ AmB, Itr Dead after relapse
29/M 84 MN (US) CyA, MMF, Pr +/ND +/+ AmB, Itr/Vor Expired†
59/F 57 IN (US) MMF, Pr +/ND ND/+ AmB, Itr Expired†
49/F 144 IN (US) SIR, Pr +/ ND/ AmB, Itr/Pos Cured
67/F 41 IN (US) CyA, MMF, Pr +/ / Itr Cured
68/M‡ 96 IA (US) CyA, MMF, Pr +/ND ND/ AmB, Itr Expired at day 7
Our case 62/M 124 Italy TAC, Pr, MMF ND/ND ND/+ AmB Expired at day 25
LT, lung transplant; CyA, cyclosporine A; TAC, tacrolimus; Pr, prednisone; MMF, mycophenolate mofetil; SIR, sirolimus; AZA, azathioprine; Amb,
amphotericin B; Vor, voriconazole; Itr, itraconazole; Pos, posaconazole.
*Donor-derived transmission.
†Death for causes not related to Histoplasma infection.
‡Patient receiving kidney and lung transplants.
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